血液恶性肿瘤及异基因造血干细胞移植受者突破性念珠菌血症的临床特征与结局
该单中心回顾性研究纳入2011-2018年中国71例血液恶性肿瘤合并突破性念珠菌血症患者,其中17例接受异基因移植。7天和30天累积死亡率分别为21.1%和31.0%,脓毒性休克、中心静脉导管移除和粒细胞恢复与7天死亡率显著相关,后两者为30天死亡率的独立预测因素。
要点
- 异基因移植组突破性念珠菌血症死亡率显著高于非移植组,但发病率无差异。
- 最常见分离菌为热带念珠菌,抗真菌药物联合为最常见一线治疗。
- 中心静脉导管移除和粒细胞恢复是30天死亡率的独立预测因素。
核心结论
- 异基因移植组突破性念珠菌血症相关死亡率更高,尽管发病率组间无显著差异。
- 及时充分抗真菌治疗并移除导管可能降低死亡率。
研究设计与样本
- 单中心回顾性研究,纳入2011-2018年中国71例血液恶性肿瘤合并突破性念珠菌血症患者,其中17例接受异基因移植。
- 收集临床和微生物学数据,记录7天和30天随访结局,比较移植与非移植组发病率和死亡率。
- 采用Kaplan-Meier法生成生存曲线,Cox回归分析识别预测因素。
主要发现
- 最常见分离菌为热带念珠菌,抗真菌药物联合为最常见一线治疗。
- 7天和30天累积死亡率分别为21.1%和31.0%,两组间差异显著。
- 脓毒性休克、中心静脉导管移除和粒细胞恢复与7天死亡率显著相关;后两者为30天死亡率独立预测因素。
临床怎么用
- 对血液恶性肿瘤合并突破性念珠菌血症患者,应及时给予充分抗真菌治疗并移除中心静脉导管。
- 异基因移植患者突破性念珠菌血症死亡率更高,需加强监测和干预。
局限性
- 单中心回顾性研究,样本量有限(71例),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antifungal prophylaxis may result in breakthrough infections in hematology patients with severe agranulocytosis, with few studies assessing risk factors and clinical outcomes of breakthrough candidemia. We described the distribution of Candida species, assessed risk factors for mortality in such patients, and determined differences in the incidence and mortality of breakthrough candidemia between patients who did or did not receive an allogeneic hematopoietic stem cell transplant. METHODS: We collected clinical and microbiological data of patients with hematologic malignancies and breakthrough candidemia from a single center. Seven-day and 30-day follow-up outcomes were recorded; the incidence and mortality of breakthrough candidemia between patients who did or did not undergo an allogeneic transplant were compared. Kaplan-Meier survival estimates were used to generate survival curves, and predictors were identified using Cox regression analyses. RESULTS: Of 71 enrolled patients, 17 received allogeneic transplants. Incidences of breakthrough candidemia were 17 of 2924 (0.58%) and 54 of 12 015 (0.45%) in the transplant and nontransplant groups, respectively (P = .35). The most common isolate was Candida tropicalis, and antifungal agent combinations were the most common first-line treatment. Cumulative mortality rates of patients were 21.1% and 31.0% at days 7 and 30, respectively, and they significantly differed between both groups. Septic shock, central venous catheter removal, and granulocyte recovery were significantly associated with 7-day mortality; the latter 2 remained independent predictors of 30-day mortality. CONCLUSIONS: Breakthrough candidemia-related mortality was higher in the allogeneic transplant group, although the incidence was not significantly different between the groups. Prompt and adequate antifungal treatment with catheter removal may reduce mortality.
引用
- Chen XC, Xu J, Wu DP, et al. Clinical Characteristics and Outcomes of Breakthrough Candidemia in 71 Hematologic Malignancy Patients and/or Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Single-center Retrospective Study From China, 2011-2018. Clin Infect Dis. 2020. PMID: 33367573. doi:10.1093/cid/ciaa1523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。